Canada authorises AstraZeneca Covid-19 vaccine

About 20 million doses will start arriving from AstraZeneca in the spring. PHOTO: AFP

OTTAWA (NYTIMES) - Canada's drug regulator authorised the AstraZeneca vaccine Friday (Feb 26) as well as a version of it developed by the Serum Institute of India.

The vaccine, which was developed with Oxford University, has not yet been authorised for use in the United States but has been key to Britain's rapid vaccination rollout.

The addition of a third vaccine, in addition to the offerings from Moderna and Pfizer-BioNTech, may help Canada alleviate a growing dissatisfaction about the sluggish pace of vaccination in the country.

"Vaccines will keep arriving faster and faster," Prime Minister Justin Trudeau said at a news conference. "We now have a third safe and effective vaccine."

Mr Trudeau said that the government expects to receive, within days, about 500,000 doses out of an order of 2 million doses of the Serum Institute version of the vaccine, known as Covishield. About 20 million doses will start arriving from AstraZeneca in the spring.

The AstraZeneca vaccine, the first virus vector-based inoculation for Covid-19 authorised in Canada, has had some stumbles.

In trials in South Africa, where a more contagious virus variant has become dominant, it did not appear to protect people from mild or moderate illness, which led the country to halt its use of the vaccine.

Drug approval officials with Health Canada said Friday that while some studies suggested that the AstraZeneca vaccine is less effective overall than others, the sample sizes used were not large enough to yield a clear conclusion.

But in Germany, many people regard it as "second-class" compared to the vaccine developed by the German company BioNTech and Pfizer, and are avoiding AstraZeneca's.

Join ST's Telegram channel and get the latest breaking news delivered to you.